For the Stigma Index see http://www.stigmaindex.org/
The Lancet CommissionsDefeating AIDS—advancing global health
Section snippets
Executive summary
After more than a decade of major achievements, the AIDS response is at a crucial juncture, both in terms of its immediate trajectory and its sustainability, as well as its place in the new global health and development agendas. In May, 2013, the UNAIDS–Lancet Commission—a diverse group of experts in HIV, health, and development, young people, people living with HIV and affected communities, activists, and political leaders—was established to investigate how the AIDS response could evolve in a
Section 1. HIV/AIDS today: still a major public health threat
Despite remarkable achievements in the past 30 years, HIV remains a major threat to public health. Although the latest available data and evidence show that the overall trend of HIV infection is generally decreasing, too many people are becoming newly infected with HIV, too many people do not know that they have HIV, and too many people are dying from AIDS-related causes. This is particularly true in major parts of sub-Saharan Africa and in various populations at high risk of HIV. With still
Section 2. What works: evidence and lessons from the AIDS response
Increasingly compelling evidence suggests that certain combinations of biomedical and behavioural prevention measures can successfully reduce AIDS-related mortality, new HIV infections, and mother-to-child transmission to very low levels and that these combinations can be implemented on a large scale in a cost-effective manner.56 Moreover, evidence is mounting of the power of prevention and treatment united with political, social, and structural interventions. Interventions that promote
Section 3. Win or lose: the AIDS response at a crossroads
This section presents our analysis of the effect and costs of four scenarios for what is possible to achieve in an AIDS response: a highly ambitious scenario agreed at the UN in 2014 that would bring the HIV epidemic to a very low level (Global Goals); two scenarios that would progress epidemic control (Best Case, Financial Constraints); and one scenario— in which current, already considerable efforts, are maintained—that would stagnate progress and allow a rise in the rate of new infections
Section 4. Better and smarter investments to control the HIV epidemic
The HIV epidemic has changed in the past 10 years: hospital wards are no longer filled with people dying of AIDS, most people living with HIV are treated on an outpatient basis, and in many countries, the epidemic is now more concentrated. The transition from a fatal disease to a chronic condition and from an emergency to a long-term maintenance response raises a new set of challenges, places different demands on countries, and necessitates new ways of thinking about effective approaches to HIV
Section 5. Research: an important foundation for a successful AIDS response
Scientific research has underpinned the AIDS response since the very first cases were reported in 19813 and must continue to do so. Here we look ahead at the scientific research agenda needed to achieve epidemic control and eventually eliminate HIV. But before discussing future HIV research priorities, we briefly describe the major funders of HIV research and highlight some general trends in HIV research funding.
Section 6. Beyond the grand convergence: AIDS and health
The scale of the AIDS challenge, coupled with waning political interest in single-disease programmes, demands that the AIDS response does things differently.175 The fundamental shift that needs to happen in the next phase of the response is to better tailor the response to people's needs and contexts, optimally use innovation, and address the structural drivers of this epidemic. In its fourth decade, the AIDS response must continue to transform both itself and the environment around it.
Much
Section 7. Towards long-term sustainable financing
Over the past 30 years, funding for the AIDS response in low-income and middle-income countries has risen from a few million dollars to $19 billion a year. Even during the global economic crisis of 2008–10, when financing from international sources levelled off temporarily, overall funding continued to increase thanks to growth in domestic contributions.187 Although overall HIV spending in 2012 and 2013 was close to the pre-crisis rate of expansion of $700 million a year, whether this growth
Section 8. Conclusion and recommendations
The main findings of our analysis are listed in panel 4. The next phase of the AIDS response must focus sharply on both prevention and treatment and on people who are at highest risk. The AIDS response must continue to be rooted in human rights and scientific evidence, build on the gains that have been made, and maximise synergies with other spheres of health and development. While mobilising additional resources, the AIDS response must remain true to its multi-stakeholder roots.
Only a massive
Conclusion
The question is no longer whether the fight against AIDS can be won; the only questions are: will it be won—and when? The answers to these questions will eventually depend on the decisions made by leaders and institutions at all different levels, in all sectors and parts of society, and on the personal choices people make in their private lives.
This online publication has been corrected. The corrected version first appeared at thelancet.com on
References (225)
- et al.
Global health 2035: a world converging within a generation
Lancet
(2013) - et al.
The political origins of health inequity: prospects for change
Lancet
(2014) - et al.
Intimate partner violence, relationship power inequity, and incidence of HIV infection in young women in South Africa: a cohort study
Lancet
(2010) - et al.
Rape perpetration by young, rural South African men: prevalence, patterns and risk factors
Soc Sci Med
(2006) - et al.
Transactional sex among women in Soweto, South Africa: prevalence, risk factors and association with HIV infection
Soc Sci Med
(2004) - et al.
Global epidemiology of HIV among female sex workers: influence of structural determinants
Lancet
(2015) - et al.
Transformation of HIV from pandemic to low-endemic levels: a public health approach to combination prevention
Lancet
(2014) - et al.
Male circumcision for HIV prevention in young men in Kisumu, Kenya: a randomised controlled trial
Lancet
(2007) - et al.
Male circumcision for HIV prevention in men in Rakai, Uganda: a randomised trial
Lancet
(2007) - et al.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial
Lancet
(2013)
Intrapartum and neonatal single-dose nevirapine compared with zidovudine for prevention of mother-to-child transmission of HIV-1 in Kampala, Uganda: 18-month follow-up of the HIVNET 012 randomised trial
Lancet
Effectiveness of an integrated intimate partner violence and HIV prevention intervention in Rakai, Uganda: analysis of an intervention in an existing cluster randomised cohort
Lancet Glob Health
Effect of a structural intervention for the prevention of intimate-partner violence and HIV in rural South Africa: a cluster randomised trial
Lancet
Effectiveness of needle-exchange programmes for prevention of HIV infection
Lancet
Towards an improved investment approach for an effective response to HIV/AIDS
Lancet
Pneumocystis pneumonia—Los Angeles
MMWR Weekly
The Gap Report
Global Health Observatory data: HIV/AIDS
Political declaration on HIV and AIDS: intensifying our efforts to eliminate HIV and AIDS
90-90-90—an ambitious treatment target to help end the AIDS epidemic
Ambitious treatment targets: writing the final chapter of the AIDS epidemic
Fast track: ending the AIDS epidemic by 2030
20th International AIDS Conference, 2014
HIV and the Law: risks, rights & health
AIDS: taking a long-term view
2013 global fact sheet
2014 progress report on the Global Plan towards the elimination of new HIV infections among children by 2015 and keeping their mothers alive
Global AIDS response progress reporting 2015
Statistics South Africa
Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013
Lancet
London meeting discussion paper. AIDS post-2015: a catalyst for convergence and results. Geneva: Joint United Nations Programme on HIV/AIDS, 2014
The 2012 National Antenatal Sentinel HIV & Herpes Simplex Type-2 Prevalence Survey in South Africa
South African national HIV Prevalence, Incidence and Behaviour Survey, 2012
AIDSinfo: epidemiological status of HIV epidemic in Uganda
Kenya AIDS Indicator Survey 2012: preliminary report
HIV among African Americans
The urban HIV epidemic in eastern and southern Africa: need for better KYE/KYR to inform adequate city responses. AIDS 2012, XIXth International AIDS Conference, July 22-27, Washington DC, USA. New Epidemic Frontiers, Oral Poster Discussion, Track C
Global report: UNAIDS report on the global AIDS epidemic 2013
Seroprevalence of HIV infection in rural South Africa
AIDS
South African national HIV prevalence, incidence, behaviour and communication survey 2008: a turning tide among teenagers?
South African national HIV Prevalence, Incidence and Behaviour Survey, 2012
Women living with HIV speak out against violence
Multi-country study on women's health and domestic violence against women
Global and regional estimates of violence against women: prevalence and health effects of intimate partner violence and non-partner sexual violence
Intimate partner violence against women in eastern Uganda: implications for HIV prevention
BMC Public Health
Increased risk of HIV in women experiencing physical partner violence in Nairobi, Kenya
AIDS Behav
HIV-positive women report more lifetime partner violence: findings from a voluntary counseling and testing clinic in Dar es Salaam, Tanzania
Am J Public Health
The Association between violence against women and HIV: evidence from a national population-based survey in Zimbabwe. Zimbabwe Working Papers, No. 4
2009 country reports on human rights practices
Global burden of transmitted HIV drug resistance and HIV-exposure categories: a systematic review and meta-analysis
AIDS
Cited by (221)
Synthesis and evaluation of 1,2,3-dithiazole inhibitors of the nucleocapsid protein of feline immunodeficiency virus (FIV) as a model for HIV infection
2022, Bioorganic and Medicinal ChemistryCitation Excerpt :The development of novel therapeutics and targets is essential to combat the emergence of resistant strains of all types of disease including viruses, bacteria and fungi. The human immunodeficiency virus (HIV) is a model example, with an expansive array of both drugs and targets that intersect at multiple points of the viral life cycle.1–2 Unfortunately, the development of resistance continues to impact the efficacy of approved medicitions.3–4
Integrating HIV and substance misuse services: a person-centred approach grounded in human rights
2022, The Lancet PsychiatryIn vitro anti-HIV, cytotoxicity and nutritional analysis of Trianthema portulacastrum L. (Aizoaceae)
2024, BMC Complementary Medicine and TherapiesA Comprehensive Review on Patents, Herbal Treatment and Clinical Trials on Acquired Immune Deficiency Syndrome
2024, Infectious Disorders - Drug Targets
- †
Listed at end of paper